Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Dr Mark Verrill

Newcastle AuthorsTitleYearFull text
Dr David Austin
Rebecca Maier
Dr Nicola Cresti
Dr Mark Verrill
Dr Wendy Osborne
et al.		Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma: The PROACT Clinical Trial2024
Dr Mark Verrill
Palbociclib in combination with aromatase inhibitors in patients ≥ 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A real-world multicentre UK study2021
Dr Mark Verrill
Health-related quality of life and work productivity in UK patients with HER2-positive breast cancer: a cross-sectional study evaluating the relationships between disease and treatment stage2020
Anantha Madhavan
Professor Alexander Phillips
Arul Immanuel
Dr Mark Verrill
Professor Michael Griffin
Surgical management of gastric gastrointestinal tumours: Comparison of local and radical resection2018
Dr David Jamieson
Dr Nicola Sunter
Sara Muro
Dr Nicola Cresti
Julieann Sludden
et al.		Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide2017
Dr Nicola Cresti
Dr Despina Televantou
Dr David Jamieson
Dr Mark Verrill
Professor Alan Boddy
Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cance2016
Dr David Jamieson
Dr Jo Lee
Dr Nicola Cresti
Melanie Griffin
Julieann Sludden
et al.		Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil2014
Dr Mark Verrill
The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib2011
Dr David Jamieson
Dr Nicola Cresti
Julieann Sludden
Melanie Griffin
Nahed Hawsawi
et al.		Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy2011
Dr Chris Plummer
Dr Mark Verrill
Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials2010
Julieann Sludden
Melanie Griffin
Mike Cole
Dr Mark Verrill
Dr David Jamieson
et al.		Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide2010
Dr Mark Verrill
Capecitabine and vinorelbine in metastatic breast cancer2009
Dr David Jamieson
Dr Nicola Cresti
Dr Mark Verrill
Professor Alan Boddy
Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma2009
Dr Chris Plummer
Dr Mark Verrill
Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk2009
Dr Fathi Azribi
Dr Petra Dildey
Dr John Wilsdon
Dr Mark Verrill
Imatinib in gastrointestinal stromal tumour (GIST): Northern cancer network experience2009
1234